Discovery of novel urea-diarylpyrazole hybrids as dual COX-2/sEH inhibitors with improved anti-inflammatory activity and highly reduced cardiovascular risks
Autor: | Maha M. Abdel-Fattah, Ahmed H. Abdelazeem, Asmaa G. Safi El-Din, Mohammed T. El-Saadi, Samir M. El-Moghazy, Noha H. Amin |
---|---|
Rok vydání: | 2020 |
Předmět: |
medicine.drug_class
Anti-Inflammatory Agents Prostacyclin Pharmacology 01 natural sciences Anti-inflammatory Cell Line Structure-Activity Relationship 03 medical and health sciences chemistry.chemical_compound Risk Factors In vivo Lactate dehydrogenase Drug Discovery medicine Humans Urea IC50 030304 developmental biology Epoxide Hydrolases 0303 health sciences Cyclooxygenase 2 Inhibitors biology 010405 organic chemistry Organic Chemistry General Medicine Glutathione 0104 chemical sciences Solubility chemistry Cyclooxygenase 2 Heart Disease Risk Factors biology.protein Celecoxib Pyrazoles Creatine kinase Biomarkers medicine.drug |
Zdroj: | European Journal of Medicinal Chemistry. 205:112662 |
ISSN: | 0223-5234 |
DOI: | 10.1016/j.ejmech.2020.112662 |
Popis: | Herein we describe our efforts to develop novel anti-inflammatory/analgesic agents devoid of known cardiovascular drawbacks. In doing so, two 1,5-diarylpyrazole series of urea linked (9a-f) and amide linked (11a-f) compounds were synthesized and evaluated in vitro as dual COX-2/sEH inhibitors using recombinant enzyme assays. The in vivo anti-inflammatory and analgesic activities were then examined using reported animal models. Compounds 9b and 9c showed the highest inhibitory activities against both COX-2 and sEH (IC50 of COX-2 = 1.85 and 1.24 μM; sEH = 0.55 and 0.40 nM, respectively), besides showing the best activity as anti-inflammatory agents. Interestingly, the cardiovascular profile of the two compounds 9b and 9c was evaluated through measuring some biochemical parameters such as prostacyclin (PGI2), lactate dehydrogenase (LDH), troponin-1 (Tn-1), tumor necrosis factor- α (TNF-α), creatine kinase-M (CK-M) and reduced glutathione (GSH) in addition to a histo-pathological study to investigate the changes in the heart muscle. The results confirmed that compounds 9b and 9c have a more favorable cardio-profile than celecoxib with much less cardiovascular risks associated with the common selective COX-2 inhibitors. Finally, the current work provided a promising approach that can be optimized to serve as a lead project to overcome the cardiovascular toxicity related to the traditional selective COX-2 inhibitors. |
Databáze: | OpenAIRE |
Externí odkaz: |